Role of PET Scan in Staging Work - up and Reevaluation after Therapy in Lymphoma.
- Author:
Young Jin YUH
;
Chul Won JUNG
;
Seock Ah IM
;
Dae Seog HEO
;
Yung Jue BANG
;
Seonyang PARK
;
June Key CHUNG
;
Myung Chul LEE
;
Byoung Kook KIM
;
Noe Kyeong KIM
- Publication Type:Original Article
- Keywords:
Lymphoma;
PET;
Staging;
Residual disease
- MeSH:
Burkitt Lymphoma;
Diagnosis;
Hodgkin Disease;
Humans;
Lymphoma*;
Lymphoma, Non-Hodgkin;
Male;
Positron-Emission Tomography*;
Recurrence;
Thorax
- From:Journal of the Korean Cancer Association
1999;31(5):1011-1017
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The authors evaluated the usefulness of the positron emission tomography (PET) with fluorine-18-tluorodeoxyglucose (8F-FDG) in initial staging, reevaluation after radical therapy and diagnosis of recurrence for non-Hodgkin's lymphoma, compaired to conventional imaging studies. MATERIALS AND METHODS: FDG-PET (ECAT Exact 47, Siemens) and conventional chest X-ray and computerized tomography (CT) were studied in patients with non-Hodgkins lymphoma. RESULTS: There were 17 patients (13 male, 4 female). Age was ranged from 18 to 62 years (median 49). By histological subgroup, diffuse large cell were 8 cases, peripheral T cell were 2 cases, diffuse mixed was 1 case, follicular mixed was 1 case, Burkitt's lymphoma was 1 case, Hodgkin's disease were 3 cases. The aims for PET were the initial staging work-up in 7 cases, the reevaluation of residual disease after radical therapy in 7 cases, the diagnosis of recurrence after complete remission in 3 cases. Between PET image and the conventional image, there were 3 cases with discrepancy, 1 case for initial staging work-up and 2 cases for the reevaluation of residual disease after radical therapy. Among the 3 cases with discrepancy, the 2 cases for the reevaluation of residual disease after radical therapy revealed that PET image reflects the involvement of lymphoma more accurately than the conventional image. CONCLUSION: The visual analysis of FDG-PET would be helpful in determining the residual disease of lymphoma after radical therapy.